Dennis Slamon

Dennis Slamon

UNVERIFIED PROFILE

Are you Dennis Slamon?   Register this Author

Register author
Dennis Slamon

Dennis Slamon

Publications by authors named "Dennis Slamon"

Are you Dennis Slamon?   Register this Author

100Publications

4488Reads

29Profile Views

Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.

Lung Cancer 2019 Sep 21;135:104-109. Epub 2019 May 21.

David Geffen School of Medicine at University of California Los Angeles, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.05.022DOI Listing
September 2019

Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.

Breast Cancer Res Treat 2019 Jun 13;175(3):617-625. Epub 2019 Mar 13.

Comprehensive Cancer Center Erlangen-EMN, Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Nuremberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05198-9DOI Listing
June 2019

Neutralization of BCL-2/X Enhances the Cytotoxicity of T-DM1 .

Mol Cancer Ther 2019 06 8;18(6):1115-1126. Epub 2019 Apr 8.

Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-18-0743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758547PMC
June 2019

Role for polo-like kinase 4 in mediation of cytokinesis.

Proc Natl Acad Sci U S A 2019 Jun 16;116(23):11309-11318. Epub 2019 May 16.

Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, CA 90095.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1818820116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561306PMC
June 2019

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

N Engl J Med 2018 Nov 20;379(20):1926-1936. Epub 2018 Oct 20.

From the Institute of Cancer Research and Royal Marsden Hospital, London (N.C.T.); David Geffen School of Medicine at University of California, Los Angeles, Santa Monica (D.J.S.), and Pfizer Oncology, San Diego (X.H.) - both in California; National Cancer Center, Goyang-si, Gyeonggi-do (J.R.), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul (S.-A.I.) - both in South Korea; Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital 4, Dnipropetrovsk, Ukraine (I.B.); National Hospital Organization Osaka National Hospital, Osaka (N.M.), and Aichi Cancer Center Hospital, Nagoya (H.I.) - both in Japan; Istituto Europeo di Oncologia (M. Colleoni) and Pfizer Oncology (C.G.) - both in Milan; Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.), and Pfizer Oncology, Collegeville (C.H.B.) - both in Pennsylvania; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada (S.V.); Brustzentrum der Universität München, Munich (N.H.), and the German Breast Group, Neu-Isenburg (S. Loibl) - both in Germany; Institut Gustave Roussy, Villejuif, France (F.A.); Pfizer Oncology, Cambridge, MA (K.P.T.); and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago (M. Cristofanilli).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1810527
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1810527DOI Listing
November 2018

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

J Clin Oncol 2018 08 3;36(24):2465-2472. Epub 2018 Jun 3.

Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9909
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9909DOI Listing
August 2018

MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer.

Mol Cancer Ther 2018 07 27;17(7):1430-1440. Epub 2018 Apr 27.

Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, UCLA, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-1049DOI Listing
July 2018

Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.

Clin Respir J 2018 Jun 15;12(6):2020-2028. Epub 2018 Feb 15.

Department of Respiratory Medicine, The Second Affiliated Hospital, Dalian Medical University, Dalian, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/crj.12769DOI Listing
June 2018

Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum.

Nat Commun 2018 03 21;9(1):1178. Epub 2018 Mar 21.

Department of Maternal-Fetal Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-03258-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862842PMC
March 2018

Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.

Genes Chromosomes Cancer 2017 08 4;56(8):589-597. Epub 2017 May 4.

Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, 90095, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22459DOI Listing
August 2017

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Cancer Cell 2017 02;31(2):225-239

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.01.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501076PMC
February 2017

An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cells.

Sci Rep 2017 02 15;7:42612. Epub 2017 Feb 15.

Department of Respiratory Medicine, The Second Hospital Affiliated to Dalian Medical University, Dalian 116027, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep42612DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309797PMC
February 2017

Palbociclib and Letrozole in Advanced Breast Cancer.

N Engl J Med 2016 11;375(20):1925-1936

From the Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica (R.S.F., D.J.S.), the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco (H.S.R.), and Pfizer, La Jolla (E.G., D.R.L., S.R.) - all in California; Hospital Gregorio Maranon, Universidad Complutense, Madrid (M.M.); U.S. Oncology Research, The Woodlands, TX (S.J.); Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); British Columbia Cancer Agency, Vancouver, Canada (K.G.); Brustzentrum der Universität München (LMU), Munich, Germany (N.H.); State Budget Medical Institution Republican Clinical Oncology, Ufa, Russia (O.N.L.); All-Ireland Cooperative Oncology Research Group, Dublin (J.M.W.); M.D. Anderson Cancer Center, University of Texas, Houston (S.M.); and Institut Curie, Paris (V.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1607303DOI Listing
November 2016

Cancer Research in the 21st Century.

Ann Surg 2016 10;264(4):555-65

University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0000000000001926DOI Listing
October 2016

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.

J Clin Oncol 2016 10;34(29):3518-3528

Michael F. Press, Denice D. Tsao-Wei, Yanling Ma, Ivonne Villalobos, and Anaamika Campeau, University of Southern California Norris Comprehensive Cancer Center; Dennis J. Slamon, Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA; Nicholas Robert, Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Vicente Valero, The University of Texas MD Anderson Cancer Center, Houston, TX; Guido Sauter and Martina Mirlacher, University of Hamburg, Hamburg; Wolfgang Eiermann, Frauenklinik vom Roten Kreuz, Munich, Germany; Marc Buyse, Hélène Fourmanoir, and Emmanuel Quinaux, International Drug Development Institute, Louvain-la-Neuve, Belgium; Tadeusz Pienkowski, Postgraduate Medical Education Center, Warsaw, Poland; John Crown, Irish Cooperative Onoclogy Research Group, St Vincent's University Hospital, Dublin, Ireland; Miguel Martin, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain; John R. Mackey, University of Alberta; Mary-Ann Lindsay, Cancer International Research Group/Translational Research in Oncology, Edmonton, Alberta, Canada; and Valerie Bee, Cancer International Research Group/Translational Research in Oncology, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.6693DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074347PMC
October 2016

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

J Clin Oncol 2016 06 18;34(18):2115-24. Epub 2016 Apr 18.

Fabrice André, Institut Gustav Roussy, INSERM Unit U981, Université Paris Sud, Villejuif, France; Sara Hurvitz and Dennis Slamon, University of California, Los Angeles, Los Angeles, CA; Angelica Fasolo, San Raffaele Scientific Institute, Milan, Italy; Ling-Ming Tseng, National Yang Ming University, Taipei, Taiwan; Guy Jerusalem, University of Liège, Liege, Belgium; Sharon Wilks, Cancer Care Center of South Texas, San Antonio, TX; Ruth O'Regan, University of Wisconsin Carbone Cancer Center, Madison, WI; Claudine Isaacs, Georgetown University, Washington DC; Masakazu Toi, Kyoto University, Sakyo-ku, Kyoto, Japan; Howard Burris, Sarah Cannon Research Institute, Nashville, TN; Wei He, Douglas Robinson, and Markus Riester, Novartis Institutes for BioMedical Research, Cambridge, MA; and Tetiana Taran and David Chen, Novartis Pharmaceuticals Corporation, East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.9161DOI Listing
June 2016

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

J Clin Oncol 2016 Feb 30;34(5):443-51. Epub 2015 Nov 30.

J. Randolph Hecht, Zev A. Wainberg, and Dennis Slamon, David Geffen School of Medicine, University of California Los Angeles, Santa Monica; Michael F. Press, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Yung-Jue Bang, Seoul National University College of Medicine; Hyun C. Chung, Yonsei Cancer Center, Yonsei Cancer Research Institute, Yonsei University College of Medicine; Joon O. Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Shukui K. Qin, People's Liberation Army Cancer Center, Nanjing Bayi Hospital, Jiangsu; Jianming M. Xu, Affiliated Hospital of the Military Medical Science Academy, Beijing; Jin Li, Cancer Hospital of Shanghai Fudan University, Shanghai, People's Republic of China; Krzysztof Jeziorski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Yaroslav Shparyk, Lviv State Regional Oncology Medical and Diagnostic Center, Lviv, Ukraine; Paulo M. Hoff, Sociedade Beneficente de Senhoras-Hospital Sirio Libanĕs, Sao Paolo, Brazil; Alberto Sobrero, Istituto di Ricovero e Cura a Carattere Scientifico San Martino Istituto Scientifico Tumori, Genova, Italy; Pamela Salman, Fundación Arturo López Pérez, Santiago, Chile; Svetlana A. Protsenko, Petrov Research Institute of Oncology, St Petersburg, Russia; Marc Buyse, International Drug Development Institute, Leuven, Belgium; Karen Afenjar, Vincent Houé, and Agathe Garcia, Translational Research in Oncology, Paris, France; Tomomi Kaneko and Saba Khan-Wasti, GlaxoSmithKline, Brentford, United Kingdom; and Yingjie Huang and Sergio Santillana, GlaxoSmithKline, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.6598DOI Listing
February 2016

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.

Breast Cancer Res 2016 Feb 9;18(1):17. Epub 2016 Feb 9.

Stanford School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-015-0661-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746893PMC
February 2016

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient.

J Immunother Cancer 2015 15;3:41. Epub 2015 Sep 15.

Division of Hematology/Oncology, UCLA School of Medicine, 11-934 Factor Building, Los Angeles, 90025 CA USA ; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, 90095 CA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-015-0084-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570757PMC
September 2015

ADRM1-amplified metastasis gene in gastric cancer.

Genes Chromosomes Cancer 2015 Aug 6;54(8):506-515. Epub 2015 Jun 6.

Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA, 90095.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22262DOI Listing
August 2015

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

J Clin Oncol 2015 Feb 1;33(4):304-11. Epub 2014 Dec 1.

Fergus J. Couch, Steven N. Hart, Xianshu Wang, Janet E. Olson, Vernon S. Pankratz, Curtis Olswold, Seth Slettedahl, Emily Hallberg, Lucia Guidugli, Jaime Davila, Susan L. Slager, and Celine M. Vachon, Mayo Clinic, Rochester, MN; Priyanka Sharma, Andrew K. Godwin, and Jennifer Klemp, University of Kansas Medical Center, Kansas City, KS; Amanda Ewart Toland, Robert Pilarski, and Charles L. Shapiro, Ohio State University, Columbus, OH; Penelope Miron and Judy Garber, Dana-Farber Cancer Institute, Boston, MA; Matthias W. Beckmann, Arif B. Ekici, and Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Wolfgang Janni, University Hospital Ulm, Ulm; Brigitte Rack, Ludwig-Maximilians University Munich, Munich; Hiltrud Brauch, Margarete Fischer-Bosch Institute of Clinical Pharmacology, University of Tubingen, Stuttgart, and German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany; Dennis J. Slamon and Peter A. Fasching, University of California, Los Angeles, Los Angeles, CA; Irene Konstantopoulou, Florentia Fostira, Athanassios Vratimos, and Drakoulis Yannoukakos, National Centre for Scientific Research "Demokritos," Athens; George Fountzilas, "Papageorgiou" Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; Liisa M. Pelttari and Heli Nevanlinna, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; William J. Tapper, Lorraine Durcan, and Diana M. Eccles, University of Southampton, Southampton; Simon S. Cross and Angela Cox, University of Sheffield, Sheffield, United Kingdom; and Song Yao and Christine Ambrosone, Roswell Park Cancer Institute, Buffalo, NY.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/4/304.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.1414
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.1414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302212PMC
February 2015

Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression.

J Biol Chem 2015 Feb 2;290(9):5566-81. Epub 2014 Dec 2.

From the David Geffen School of Medicine, Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California 90095, Iris Cantor-UCLA Women's Health Center, Los Angeles, California 90095

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M114.606459DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342471PMC
February 2015

In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.

Breast Cancer Res Treat 2015 Feb 8;149(3):669-80. Epub 2015 Feb 8.

Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3282-xDOI Listing
February 2015

Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.

Authors:
Amanda B Spurdle Fergus J Couch Michael T Parsons Lesley McGuffog Daniel Barrowdale Manjeet K Bolla Qin Wang Sue Healey Rita Schmutzler Barbara Wappenschmidt Kerstin Rhiem Eric Hahnen Christoph Engel Alfons Meindl Nina Ditsch Norbert Arnold Hansjoerg Plendl Dieter Niederacher Christian Sutter Shan Wang-Gohrke Doris Steinemann Sabine Preisler-Adams Karin Kast Raymonda Varon-Mateeva Steve Ellis Debra Frost Radka Platte Jo Perkins D Gareth Evans Louise Izatt Ros Eeles Julian Adlard Rosemarie Davidson Trevor Cole Giulietta Scuvera Siranoush Manoukian Bernardo Bonanni Frederique Mariette Stefano Fortuzzi Alessandra Viel Barbara Pasini Laura Papi Liliana Varesco Rosemary Balleine Katherine L Nathanson Susan M Domchek Kenneth Offitt Anna Jakubowska Noralane Lindor Mads Thomassen Uffe Birk Jensen Johanna Rantala Åke Borg Irene L Andrulis Alexander Miron Thomas V O Hansen Trinidad Caldes Susan L Neuhausen Amanda E Toland Heli Nevanlinna Marco Montagna Judy Garber Andrew K Godwin Ana Osorio Rachel E Factor Mary B Terry Timothy R Rebbeck Beth Y Karlan Melissa Southey Muhammad Usman Rashid Nadine Tung Paul D P Pharoah Fiona M Blows Alison M Dunning Elena Provenzano Per Hall Kamila Czene Marjanka K Schmidt Annegien Broeks Sten Cornelissen Senno Verhoef Peter A Fasching Matthias W Beckmann Arif B Ekici Dennis J Slamon Stig E Bojesen Børge G Nordestgaard Sune F Nielsen Henrik Flyger Jenny Chang-Claude Dieter Flesch-Janys Anja Rudolph Petra Seibold Kristiina Aittomäki Taru A Muranen Päivi Heikkilä Carl Blomqvist Jonine Figueroa Stephen J Chanock Louise Brinton Jolanta Lissowska Janet E Olson Vernon S Pankratz Esther M John Alice S Whittemore Dee W West Ute Hamann Diana Torres Hans Ulrich Ulmer Thomas Rüdiger Peter Devilee Robert A E M Tollenaar Caroline Seynaeve Christi J Van Asperen Diana M Eccles William J Tapper Lorraine Durcan Louise Jones Julian Peto Isabel dos-Santos-Silva Olivia Fletcher Nichola Johnson Miriam Dwek Ruth Swann Anita L Bane Gord Glendon Anna M Mulligan Graham G Giles Roger L Milne Laura Baglietto Catriona McLean Jane Carpenter Christine Clarke Rodney Scott Hiltrud Brauch Thomas Brüning Yon-Dschun Ko Angela Cox Simon S Cross Malcolm W R Reed Jan Lubinski Katarzyna Jaworska-Bieniek Katarzyna Durda Jacek Gronwald Thilo Dörk Natalia Bogdanova Tjoung-Won Park-Simon Peter Hillemanns Christopher A Haiman Brian E Henderson Fredrick Schumacher Loic Le Marchand Barbara Burwinkel Frederik Marme Harald Surovy Rongxi Yang Hoda Anton-Culver Argyrios Ziogas Maartje J Hooning J Margriet Collée John W M Martens Madeleine M A Tilanus-Linthorst Hermann Brenner Aida Karina Dieffenbach Volke Arndt Christa Stegmaier Robert Winqvist Katri Pylkäs Arja Jukkola-Vuorinen Mervi Grip Annika Lindblom Sara Margolin Vijai Joseph Mark Robson Rohini Rau-Murthy Anna González-Neira José Ignacio Arias Pilar Zamora Javier Benítez Arto Mannermaa Vesa Kataja Veli-Matti Kosma Jaana M Hartikainen Paolo Peterlongo Daniela Zaffaroni Monica Barile Fabio Capra Paolo Radice Soo H Teo Douglas F Easton Antonis C Antoniou Georgia Chenevix-Trench David E Goldgar

Breast Cancer Res 2014 Dec 23;16(6):3419. Epub 2014 Dec 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-014-0474-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352262PMC
December 2014

PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing.

PLoS One 2014 24;9(2):e89464. Epub 2014 Feb 24.

Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America ; Department of Biological Chemistry, University of California Los Angeles, Los Angeles, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0089464PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933565PMC
December 2014

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

J Natl Cancer Inst 2014 Oct 30;106(10). Epub 2014 Sep 30.

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA (GEK, HH, JD, CG, HWC, DJS); Department of Health Sciences Research (CW, ELG), Department of Gynecologic Surgery (BW, SD, WC, BG, KCP), Department of Medicine (KRK, LCH), and Department of Pathology (GK), Mayo Clinic, Rochester, MN; Department of Biostatistics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA (HJW).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271115PMC
October 2014

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

Clin Cancer Res 2014 Jun 11;20(11):2947-58. Epub 2014 Apr 11.

Authors' Affiliations: Oncology Research Therapeutic Area, Genomics Analysis Unit, Department of Pathology, Amgen Inc., Thousand Oaks; Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; and The Ludwig Center and the Howard Hughes Medical Institute, Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138720PMC
June 2014

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

Mol Cancer 2014 Jun 24;13:157. Epub 2014 Jun 24.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-13-157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230643PMC
June 2014

HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.

Breast Cancer Res Treat 2014 May 29;145(1):193-203. Epub 2014 Mar 29.

Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-2922-xDOI Listing
May 2014

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Gynecol Oncol 2014 Feb 22;132(2):334-42. Epub 2013 Dec 22.

Division of Hematology/Oncology and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.12.021DOI Listing
February 2014

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.

Breast Cancer Res Treat 2013 Oct 5;141(3):397-408. Epub 2013 Oct 5.

Division of Hematology/Oncology, Department of Medicine, Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, Los Angeles, CA, 90095, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-013-2702-z
Publisher Site
http://dx.doi.org/10.1007/s10549-013-2702-zDOI Listing
October 2013

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.

Mol Cancer Ther 2013 Jun 14;12(6):890-900. Epub 2013 Mar 14.

Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0998DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681857PMC
June 2013

Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.

Hepatology 2013 May 1;57(5):1838-46. Epub 2013 Apr 1.

Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.26223DOI Listing
May 2013

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.

Mol Cancer Ther 2013 May 26;12(5):632-42. Epub 2013 Feb 26.

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0999DOI Listing
May 2013

Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.

Mol Cancer Ther 2013 Apr 8;12(4):509-19. Epub 2013 Feb 8.

University of California Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, Santa Monica, CA 90404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0507DOI Listing
April 2013

Genome-wide association studies identify four ER negative-specific breast cancer risk loci.

Authors:
Montserrat Garcia-Closas Fergus J Couch Sara Lindstrom Kyriaki Michailidou Marjanka K Schmidt Mark N Brook Nick Orr Suhn Kyong Rhie Elio Riboli Heather S Feigelson Loic Le Marchand Julie E Buring Diana Eccles Penelope Miron Peter A Fasching Hiltrud Brauch Jenny Chang-Claude Jane Carpenter Andrew K Godwin Heli Nevanlinna Graham G Giles Angela Cox John L Hopper Manjeet K Bolla Qin Wang Joe Dennis Ed Dicks Will J Howat Nils Schoof Stig E Bojesen Diether Lambrechts Annegien Broeks Irene L Andrulis Pascal Guénel Barbara Burwinkel Elinor J Sawyer Antoinette Hollestelle Olivia Fletcher Robert Winqvist Hermann Brenner Arto Mannermaa Ute Hamann Alfons Meindl Annika Lindblom Wei Zheng Peter Devillee Mark S Goldberg Jan Lubinski Vessela Kristensen Anthony Swerdlow Hoda Anton-Culver Thilo Dörk Kenneth Muir Keitaro Matsuo Anna H Wu Paolo Radice Soo Hwang Teo Xiao-Ou Shu William Blot Daehee Kang Mikael Hartman Suleeporn Sangrajrang Chen-Yang Shen Melissa C Southey Daniel J Park Fleur Hammet Jennifer Stone Laura J Van't Veer Emiel J Rutgers Artitaya Lophatananon Sarah Stewart-Brown Pornthep Siriwanarangsan Julian Peto Michael G Schrauder Arif B Ekici Matthias W Beckmann Isabel Dos Santos Silva Nichola Johnson Helen Warren Ian Tomlinson Michael J Kerin Nicola Miller Federick Marme Andreas Schneeweiss Christof Sohn Therese Truong Pierre Laurent-Puig Pierre Kerbrat Børge G Nordestgaard Sune F Nielsen Henrik Flyger Roger L Milne Jose Ignacio Arias Perez Primitiva Menéndez Heiko Müller Volker Arndt Christa Stegmaier Peter Lichtner Magdalena Lochmann Christina Justenhoven Yon-Dschun Ko Taru A Muranen Kristiina Aittomäki Carl Blomqvist Dario Greco Tuomas Heikkinen Hidemi Ito Hiroji Iwata Yasushi Yatabe Natalia N Antonenkova Sara Margolin Vesa Kataja Veli-Matti Kosma Jaana M Hartikainen Rosemary Balleine Chiu-Chen Tseng David Van Den Berg Daniel O Stram Patrick Neven Anne-Sophie Dieudonné Karin Leunen Anja Rudolph Stefan Nickels Dieter Flesch-Janys Paolo Peterlongo Bernard Peissel Loris Bernard Janet E Olson Xianshu Wang Kristen Stevens Gianluca Severi Laura Baglietto Catriona McLean Gerhard A Coetzee Ye Feng Brian E Henderson Fredrick Schumacher Natalia V Bogdanova France Labrèche Martine Dumont Cheng Har Yip Nur Aishah Mohd Taib Ching-Yu Cheng Martha Shrubsole Jirong Long Katri Pylkäs Arja Jukkola-Vuorinen Saila Kauppila Julia A Knight Gord Glendon Anna Marie Mulligan Robertus A E M Tollenaar Caroline M Seynaeve Mieke Kriege Maartje J Hooning Ans M W van den Ouweland Carolien H M van Deurzen Wei Lu Yu-Tang Gao Hui Cai Sabapathy P Balasubramanian Simon S Cross Malcolm W R Reed Lisa Signorello Qiuyin Cai Mitul Shah Hui Miao Ching Wan Chan Kee Seng Chia Anna Jakubowska Katarzyna Jaworska Katarzyna Durda Chia-Ni Hsiung Pei-Ei Wu Jyh-Cherng Yu Alan Ashworth Michael Jones Daniel C Tessier Anna González-Neira Guillermo Pita M Rosario Alonso Daniel Vincent Francois Bacot Christine B Ambrosone Elisa V Bandera Esther M John Gary K Chen Jennifer J Hu Jorge L Rodriguez-Gil Leslie Bernstein Michael F Press Regina G Ziegler Robert M Millikan Sandra L Deming-Halverson Sarah Nyante Sue A Ingles Quinten Waisfisz Helen Tsimiklis Enes Makalic Daniel Schmidt Minh Bui Lorna Gibson Bertram Müller-Myhsok Rita K Schmutzler Rebecca Hein Norbert Dahmen Lars Beckmann Kirsimari Aaltonen Kamila Czene Astrid Irwanto Jianjun Liu Clare Turnbull Nazneen Rahman Hanne Meijers-Heijboer Andre G Uitterlinden Fernando Rivadeneira Curtis Olswold Susan Slager Robert Pilarski Foluso Ademuyiwa Irene Konstantopoulou Nicholas G Martin Grant W Montgomery Dennis J Slamon Claudia Rauh Michael P Lux Sebastian M Jud Thomas Bruning Joellen Weaver Priyanka Sharma Harsh Pathak Will Tapper Sue Gerty Lorraine Durcan Dimitrios Trichopoulos Rosario Tumino Petra H Peeters Rudolf Kaaks Daniele Campa Federico Canzian Elisabete Weiderpass Mattias Johansson Kay-Tee Khaw Ruth Travis Françoise Clavel-Chapelon Laurence N Kolonel Constance Chen Andy Beck Susan E Hankinson Christine D Berg Robert N Hoover Jolanta Lissowska Jonine D Figueroa Daniel I Chasman Mia M Gaudet W Ryan Diver Walter C Willett David J Hunter Jacques Simard Javier Benitez Alison M Dunning Mark E Sherman Georgia Chenevix-Trench Stephen J Chanock Per Hall Paul D P Pharoah Celine Vachon Douglas F Easton Christopher A Haiman Peter Kraft

Nat Genet 2013 Apr;45(4):392-8, 398e1-2

1] Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, UK. [2] Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK. [3].

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.2561DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771695PMC
April 2013

Systemic therapy for metastatic renal cell carcinoma: a review and update.

Rev Urol 2012 ;14(3-4):65-78

Institute of Urologic Oncology, Department of Urology, The David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602729PMC
March 2013

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.

Breast Cancer Res Treat 2013 Feb 3;137(3):755-66. Epub 2013 Jan 3.

Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Fulham Road, Chelsea, London, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2399-4
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2399-4DOI Listing
February 2013

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer.

Int J Mol Sci 2013 Feb 1;14(2):3094-109. Epub 2013 Feb 1.

Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms14023094DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588033PMC
February 2013

Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.

Mol Cancer Res 2012 Dec 15;10(12):1597-606. Epub 2012 Oct 15.

Division of Cancer Research and Training, Department of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-12-0155-TDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732195PMC
December 2012

The role of genetic breast cancer susceptibility variants as prognostic factors.

Authors:
Peter A Fasching Paul D P Pharoah Angela Cox Heli Nevanlinna Stig E Bojesen Thomas Karn Annegien Broeks Flora E van Leeuwen Laura J van't Veer Renate Udo Alison M Dunning Dario Greco Kristiina Aittomäki Carl Blomqvist Mitul Shah Børge G Nordestgaard Henrik Flyger John L Hopper Melissa C Southey Carmel Apicella Montserrat Garcia-Closas Mark Sherman Jolanta Lissowska Caroline Seynaeve Petra E A Huijts Rob A E M Tollenaar Argyrios Ziogas Arif B Ekici Claudia Rauh Arto Mannermaa Vesa Kataja Veli-Matti Kosma Jaana M Hartikainen Irene L Andrulis Hilmi Ozcelik Anna-Marie Mulligan Gord Glendon Per Hall Kamila Czene Jianjun Liu Jenny Chang-Claude Shan Wang-Gohrke Ursula Eilber Stefan Nickels Thilo Dörk Maria Schiekel Michael Bremer Tjoung-Won Park-Simon Graham G Giles Gianluca Severi Laura Baglietto Maartje J Hooning John W M Martens Agnes Jager Mieke Kriege Annika Lindblom Sara Margolin Fergus J Couch Kristen N Stevens Janet E Olson Matthew Kosel Simon S Cross Sabapathy P Balasubramanian Malcolm W R Reed Alexander Miron Esther M John Robert Winqvist Katri Pylkäs Arja Jukkola-Vuorinen Saila Kauppila Barbara Burwinkel Frederik Marme Andreas Schneeweiss Christof Sohn Georgia Chenevix-Trench Diether Lambrechts Anne-Sophie Dieudonne Sigrid Hatse Erik van Limbergen Javier Benitez Roger L Milne M Pilar Zamora José Ignacio Arias Pérez Bernardo Bonanni Bernard Peissel Bernard Loris Paolo Peterlongo Preetha Rajaraman Sara J Schonfeld Hoda Anton-Culver Peter Devilee Matthias W Beckmann Dennis J Slamon Kelly-Anne Phillips Jonine D Figueroa Manjeet K Humphreys Douglas F Easton Marjanka K Schmidt

Hum Mol Genet 2012 Sep 24;21(17):3926-39. Epub 2012 Apr 24.

University Breast Center, Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

View Article

Download full-text PDF

Source
http://hmg.oxfordjournals.org/content/21/17/3926.full.pdf
Web Search
http://www.hmg.oxfordjournals.org/cgi/doi/10.1093/hmg/dds159
Publisher Site
http://dx.doi.org/10.1093/hmg/dds159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412377PMC
September 2012

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.

BMC Cancer 2012 Jan 14;12:16. Epub 2012 Jan 14.

Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, CA 90404-2429, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-12-16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292503PMC
January 2012

Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis.

Mol Cancer Ther 2011 Aug 13;10(8):1500-8. Epub 2011 Jun 13.

Division of Hematology-Oncology, Department of Medicine, University of California-Los Angeles School of Medicine, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0046DOI Listing
August 2011

Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK.

Genes Chromosomes Cancer 2011 Jun 22;50(6):434-41. Epub 2011 Mar 22.

Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20868DOI Listing
June 2011

Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization.

Genes Chromosomes Cancer 2011 Feb;50(2):95-112

Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20835DOI Listing
February 2011

Tissue microarrays from frozen tissues-OCT technique.

Methods Mol Biol 2010 ;664:73-80

Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-60761-806-5_8DOI Listing
December 2010

Periostin promotes ovarian cancer angiogenesis and metastasis.

Gynecol Oncol 2010 Nov 4;119(2):337-44. Epub 2010 Aug 4.

Division of Hematology-Oncology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2010.07.008DOI Listing
November 2010

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Science 2010 Oct 8;330(6001):228-31. Epub 2010 Sep 8.

Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.1196333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076894PMC
October 2010

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Neoplasia 2010 Aug;12(8):637-49

Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915408PMC
http://dx.doi.org/10.1593/neo.10414DOI Listing
August 2010

FOXO1A is a target for HER2-overexpressing breast tumors.

Cancer Res 2010 Jul 15;70(13):5475-85. Epub 2010 Jun 15.

Divisions of Cancer Research and Training, Department of Medicine, Charles R. Drew University of Medicine and Science, University of California at Los Angeles David Geffen School of Medicine, Los Angeles, California 90059, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-0176DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896450PMC
July 2010

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

Mol Cancer Ther 2010 Jun 25;9(6):1489-502. Epub 2010 May 25.

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095-7077, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-09-1171DOI Listing
June 2010